How much funding has Hologen raised?

Hologen has raised $150M in total funding. Their latest funding round was Series A. Key investors include Averin (lead), 2468 Ventures, Gaingels, Mana Ventures, Menon VC, SW7 Group, Eric Schmidt.

Where is Hologen headquartered?

Hologen is headquartered in London, United Kingdom. The company has a team of 11-50 people.

What does Hologen do?

Hologen operates in the AI in Biotech / Drug Discovery sector. Clinical-stage AI biotech co-founded by Eric Schmidt building 'Large Medicine Models' — multimodal generative AI trained on clinical and real-world patient data to de-risk and optimize drug development. Uses large-scale, multi-modal generative AI foundation models (Large Medicine Models) trained on clinical and real-world data to improve the design, evaluation, and success rate of late-stage clinical trials, reducing the cost and risk of bringing new treatments to market.

When was Hologen founded?

Hologen was founded in 2023. It is based in London, United Kingdom.

Who is the CEO of Hologen?

Roland W. Tegeder, PhD is the CEO of Hologen. The company was founded in 2023.

Where is Hologen located?

Hologen is headquartered in London, United Kingdom.

What funding stage is Hologen at?

Hologen is currently at the Series A stage.

How many employees does Hologen have?

Hologen has approximately 11-50 employees.

Hologen

Category: AI in Biotech / Drug Discovery

Clinical-stage AI biotech co-founded by Eric Schmidt building 'Large Medicine Models' — multimodal generative AI trained on clinical and real-world patient data to de-risk and optimize drug development. Hologen was founded in 2023. The company is led by Roland W. Tegeder, PhD. Based in London, United Kingdom. Team size: 11-50. Total funding raised: $150M. Latest round: Series A. Key investors include Averin (lead), 2468 Ventures, Gaingels, Mana Ventures, Menon VC, SW7 Group, Eric Schmidt.

Founded: 2023
Headquarters: London, United Kingdom
Team size: 11-50
Total funding: $150M

Value proposition

Uses large-scale, multi-modal generative AI foundation models (Large Medicine Models) trained on clinical and real-world data to improve the design, evaluation, and success rate of late-stage clinical trials, reducing the cost and risk of bringing new treatments to market.

Products and solutions

Large Medicine Models (LMMs) — multimodal generative foundation models combining biomedical, clinical trial, and real-world patient data, co-development/co-investment vehicles for late-stage clinical assets (e.g., Hologen Neuro AI joint venture for neurological gene therapies).

Unique value

Combines Google-scale AI leadership (Eric Schmidt) with deep clinical/biomedical academic ties (UCL, King's College London, Imperial College London) and a direct co-investment model in clinical assets, differentiating from pure AI-software drug discovery vendors.

Target customer

Pharmaceutical and biotech companies with clinical-stage drug assets (e.g., gene therapy developers) seeking to de-risk and accelerate trial design and execution.

Industries served

Biotech / Pharma, Clinical Trials, Drug Development, Neurology (Parkinson's), Gene Therapy

Technology advantage

Proprietary multimodal generative 'Large Medicine Model' architecture trained jointly on clinical trial and real-world patient data; spin-out academic pedigree from UCL/KCL; capital-intensive co-development model (invests directly in clinical assets rather than only licensing software/insights).

How they differentiate

Unlike discovery-stage AI drug design platforms (e.g., Insilico, Exscientia), Hologen focuses on late-stage clinical trial de-risking and directly co-funds/co-develops clinical assets (e.g., $230-430M JV with MeiraGTx) rather than purely licensing AI insights.

Main competitors

Insilico Medicine, Recursion Pharmaceuticals, Owkin / BenevolentAI / Valo Health (AI-driven drug discovery/development platforms)

Key partnerships

MeiraGTx — broad strategic collaboration, formed joint venture 'Hologen Neuro AI' (Hologen majority stake, MeiraGTx 30%) with up to $230-430M in committed capital to fund Parkinson's (AAV-GAD) and obesity gene therapy programs through Phase 3, academic ties to University College London (UCL), King's College London (KCL), and Imperial College London, minority stake taken in MeiraGTx's manufacturing subsidiary.

Notable customers

MeiraGTx (strategic collaboration / joint venture partner, not a traditional customer)

Major milestones

2023: Founded, spun out of UCL/KCL research, Jan 2026: Reported to be raising $150M Series A at $850M valuation led by Averin (STAT News), 2026: Announced strategic collaboration and joint venture 'Hologen Neuro AI' with MeiraGTx, committing up to $230-430M to advance Parkinson's (AAV-GAD) and obesity gene therapy programs through Phase 3.

Market positioning

Well-capitalized, high-profile challenger in AI-driven clinical development, leveraging Eric Schmidt's brand and network to secure a large Series A at a near-unicorn valuation while still pre-revenue/clinical-stage.

Geographic focus

UK/Europe academic and biotech ecosystem with global (US-heavy) AI drug discovery competitive set.

About Roland W. Tegeder, PhD

Former Partner, Goldman Sachs (Managing Director, Tokyo, cross-asset structured products); Founding Partner, SW7 Group (technology investment/incubation firm); Chairman & Founding Partner, RAIN Foundation LBG. PhD.

Latest news about Hologen

Hologen is raising 150 million dollars in Series A funding to scale its Large Medicine Models for clinical trial optimization. Co-founded by Eric Schmidt, the startup recently secured a 200 million do

More AI in Biotech / Drug Discovery companies

Official website: https://hologen.ai